Uveitis associated with immunotherapy and its response to monotherapy with difluprednate: A case report.

Abstract

Nivolumab and ipilimumab are immune checkpoint inhibitors widely used for the treatment of metastatic melanoma. They can cause various adverse effects in a significant percentage of treated patients, including uveitis. Symptoms include decreased visual acuity, pain, redness, and photophobia, which typically resolve with appropriate anti-inflammatory therapy. The aim of this work is to report a case of uveitis in a patient on ipilimumab and nivolumab for the treatment of metastatic melanoma, as well as the response to therapy with difluprednate.